Visit Aggrego Advances hub to learn more about the late breaking developments from the POSEIDON trial 

Top Stories
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients With Multiple Myeloma

On June 3rd, Johnson & Johnson announced updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational bispecific antibody talquetamab in the treatment of patients with r

PR Newswire
Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

According to data presented at ASCO 2023 on June 3rd, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the first-ever results from the Phase 1b RedirecTT-1 study of teclistam

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

Phase 1 clinical trial results demonstrate that in patients with nasopharyngeal carcinoma, EGFR-mutated non-small cell lung cancer, and other advanced soli

Journal for ImmunoTherapy of Cancer


Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.